

Global Therapeutic Landscape of Phenylketonuria (PKU) Pipeline Review H1, 2018

PUNE, MAHARASHTRA, INDIA, February 12, 2018 /EINPresswire.com/ --WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report "Phenylketonuria (PKU) - Pipeline Review, H1 2018"

Phenylketonuria (PKU)

Overview

Phenylketonuria (also called PKU), is a rare inherited disorder that causes an amino acid called phenylalanine to build up in body. Symptoms include intellectual



disability, psychiatric disorders, hyperactivity, skin rashes, poor bone strength and abnormally small head.

Click here for sample report @ <u>https://www.wiseguyreports.com/sample-request/2880291-phenylketonuria-pku-pipeline-review-h1-2018</u>

Top Companies mentioned

American Gene Technologies International Inc

BioMarin Pharmaceutical Inc

Censa Pharmaceuticals Inc

Codexis Inc

EryDel SPA

Erytech Pharma SA

MipSalus ApS

Synlogic Inc

Synthetic Biologics Inc

Ultragenyx Pharmaceutical Inc

Phenylketonuria (PKU) Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Phenylketonuria (PKU) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Phenylketonuria (PKU), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

It also reviews key players involved in Phenylketonuria (PKU) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 2, 5, 1 and 4 respectively.

Phenylketonuria (PKU) - Competitive Analysis

Key players are making innovative developments in Phenylketonuria (PKU) industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The report provides a snapshot of the global therapeutic landscape for Phenylketonuria (PKU)

The report reviews Phenylketonuria (PKU) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.

The report reviews key players involved in Phenylketonuria (PKU) targeted therapeutics and enlists all their major and minor projects.

The report assesses Phenylketonuria (PKU) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.

The report summarizes all the dormant and discontinued pipeline projects.

.Continued

For Detailed Reading Please visit @ <u>https://www.wiseguyreports.com/reports/2880291-phenylketonuria-pku-pipeline-review-h1-2018</u>

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent wiseguyreports +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.